Nordic ListingsIssuer Report
Ortoma AB: Quarterly Trading Report 2025 Q3
Ortoma AB: Quarterly Trading Report 2025 Q3https://view.news.eu.nasdaq.com/view?id=bf36cdcedd35d1eac37b13247ba84c50b&lang=en&src=omxlink
Ortoma AB: Quarterly Trading Report 2025 Q3
Earlier from Ortoma
- ORT_B: FDA approval and milestone payment fueled record sales and profit growth in H1 2025
- ORT_B: Q1 2025 saw Ortoma achieve record revenue and regulatory milestones, fueling profitable growth
- ORT_B: Revenue up, EBITDA positive, and US commercialization underway pending approvals
- ORT_B: Record US order and strong Q3 sales drive Ortoma's positive momentum
- ORT_B: Milestone-driven revenue growth offset by lower earnings as Ortoma invests in commercialization
Later from Ortoma
- Ortoma Receives Orders From Japan
- Ortoma Q3 Net Sales Amounted To SEK 2.4 Million
- Ortoma Preliminary 2025 Operating Revenues At SEK 67 Mln
- Ortoma: Regulatory Win In Australia For OTS Hip
- ORT_B: 2025 revenue grew to 64.6 MSEK, but net loss deepened to -19.2 MSEK amid commercialization efforts
Follow Ortoma into a list and get an email when it puts out news.
Follow Ortoma